Imperial College London
Portrait Picture

ProfessorWendyBarclay

Faculty of Medicine, Department of Infectious Disease

Action Medical Research Chair Virology. Head of Department
 
 
 
//

Contact

 

+44 (0)20 7594 5035w.barclay

 
 
//

Location

 

416Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Leach:2021:10.1038/s41467-021-24342-y,
author = {Leach, DA and Mohr, A and Giotis, ES and Cil, E and Isac, AM and Yates, LL and Barclay, WS and Zwacka, RM and Bevan, C and Brooke, GN},
doi = {10.1038/s41467-021-24342-y},
journal = {Nature Communications},
pages = {1--12},
title = {The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells},
url = {http://dx.doi.org/10.1038/s41467-021-24342-y},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - SARS-CoV-2 attacks various organs, most destructively the lung, and cellular entry requires two host cell surface proteins: ACE2 and TMPRSS2. Downregulation of one or both of these is thus a potential therapeutic approach for COVID-19.  TMPRSS2 is a known target of the androgen receptor, a ligand-activated transcription factor; androgen receptor activation increases TMPRSS2 levels in various tissues, most notably prostate.  We show here that treatment with the antiandrogen enzalutamide – a well-tolerated drug widely used in advanced prostate cancer – reduces TMPRSS2 levels in human lung cells and in mouse lung.  Importantly, antiandrogens significantly reduced SARS-CoV-2 entry and infection in lung cells.  In support of this experimental data, analysis of existing datasets shows striking co-expression of AR and TMPRSS2, including in specific lung cell types targeted by SARS-CoV-2. Together, the data presented provides strong evidence to support clinical trials to assess the efficacy of antiandrogens as a treatment option for COVID-19.
AU  - Leach,DA
AU  - Mohr,A
AU  - Giotis,ES
AU  - Cil,E
AU  - Isac,AM
AU  - Yates,LL
AU  - Barclay,WS
AU  - Zwacka,RM
AU  - Bevan,C
AU  - Brooke,GN
DO  - 10.1038/s41467-021-24342-y
EP  - 12
PY  - 2021///
SN  - 2041-1723
SP  - 1
TI  - The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-021-24342-y
UR  - https://www.nature.com/articles/s41467-021-24342-y
UR  - http://hdl.handle.net/10044/1/89864
VL  - 12
ER  -
Download